Researchers from the University of Huddersfield present new data and announce further studies which show great potential for the development of a for a noninvasive multiple sclerosis diagnostic tool which uses GC–MS.
Photo Credit: ralwel/stock.adobe.com
As a chronic neurological disease, multiple sclerosis affects the brain and spinal cord causing a wide range of symptoms, from problems with vision and movement to sensation or balance. The condition can cause serious disability, but the range and severity of symptoms varies with mild forms also existing.
Diagnosis of the disease is based upon visible symptoms of the disease and confirmed by examination of the cerebrospinal fluids (CSF), an invasive and painful procedure. Magnetic resonance imaging of the brain and spinal cord can also be used for diagnosis, and according to a recent publication, could also predict how their condition will progress, including how disabled they are likely to become (1). However, as routine diagnostic tools, neither technique is adequate.
“There are over 100,000 people with multiple sclerosis in the UK and we often hear that the path to diagnosis is an incredibly stressful time,” said Susan Kohlhaas, Multiple Sclerosis Society Director of Research.
As such, there is a drastic need for a noninvasive diagnostic tool. One promising avenue is that of biomarker analysis, with a 2017 (2) preliminary study identifying numerous biomarkers in the breath of multiple sclerosis patients.
That initial study utilized gas chromatography–mass spectrometry (GC–MS) and a nanomaterial-based sensor array to identify significant differences in the volatile organic compounds (VOCs) of multiple sclerosis patients and controls. The new study will confirm the initial results and look to use these results to create a diagnostic tool.
Speaking at the Multiple Sclerosis Society Multiple Sclerosis Frontiers Conference in Bath, UK, Phoebe Tate from the University of Huddersfield’s Centre for Biomarker Research said “The new work looked at more subtypes of multiple sclerosis, whereas the 2017 study just looked at relapsing multiple sclerosis. Additionally, the new study also looked at primary multiple sclerosis and secondary multiple sclerosis in to find out if the different subtypes, such as the more inflammatory, actively demyelinating relapsing-remitting multiple sclerosis, and the less inflammatory, progressive primary progressive multiple sclerosis and secondary progressive multiple sclerosis, can be differentiated by a breath test, as well as finding a diagnostic test.”
“The techniques used for diagnosis are invasive, expensive, and often laborious, so this exciting development would address a major unmet need. Having a lumbar puncture and even an MRI scan can be an uncomfortable and unsettling experience, which we know people with multiple sclerosis are keen to change,” said Kohlhaas.
The researchers are now preparing a larger three-year study with 500 people, which will start later in 2019. This will determine if the test can be rolled out across the NHS, and if it can help to determine how multiple sclerosis progresses.
For more information, please visit: www.mssociety.org.uk
References
Pittcon 2025: Xiao Su Discusses His Work in Electrochemical Separations
March 13th 2025In this video interview with Xiao Su, he dives deeper into the research that he and his team are conducting with redox-active polymers and the applicability of electrochemical approaches in separation science.
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ions used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.
Pittcon 2025: Kate Perrault Uptmor Talks About Multidimensional GC and Mentorship
March 13th 2025In our interview with Kate Perrault Uptmor, we asked her about the resources available for those interested in learning more about multidimensional chromatography, and current trends happening in separation science that are of particular note.
Analyzing Effects of Adverse Cardiovascular Events on Chronic Kidney Disease with HPLC
March 13th 2025Researchers investigated the potential association between plasma apolipoprotein M (APOM) levels and the risk of adverse cardiovascular outcomes in individuals with chronic kidney disease (CKD). Plasma sphingosine-1-phosphate (S1P) levels were measured by high performance liquid chromatography (HPLC).